Clinical Implications of Unique Drug Interaction Between Extended Release Tacrolimus and Phenytoin

Abstract

Keywords

kidney transplant recipient subtherapeutic level tacrolimus envarsus XR calcineurin inhibitor

Get full access to this article

View all access options for this article.

References

Rostaing

Bunnapradist

Grinyó

, et al. Novel once-daily extended-release tacrolimus versus twice-daily tacrolimus in de novo kidney transplant recipients: two-year results of phase 3, double-blind, randomized trial. Am J Kidney Dis. 2016;67(4):648–659. doi:10.1053/j.ajkd.2015.10.024.

Tremblay

Nigro

Weinberg

Woodle

Alloway

. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): an open-label, prospective, randomized, two-arm, three-period crossover study. Am J Transplant. 2017;17(2):432–442. doi:10.1111/ajt.13935.

Wada

Takada

Ueda

, et al. Drug interactions between tacrolimus and phenytoin in Japanese heart transplant recipients: 2 case reports. Int J Clin Pharmacol Ther. 2007;45(9):524–528.

Thelen

Dressman

. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol. 2009;61(5):541–558. doi:10.1211/jpp/61.05.002.

Williamson

Purkayastha

Hunter

, et al. Quantitative protein determination for CYP induction via LC-MS/MS. Proteomics. 2011;11(1):33–41. doi:10.1002/pmic.201000456.